A Bristol-Myers Squibb (NYSE:BMY) lung disease drug candidate is moving ahead in clinical development under a new partnership with Duke University.
Under the alliance, Bristol-Myers scientists will work with the Duke Translational Medicine Institute on phase 2 clinical development of BMS-986202, a compound being studied as a treatment for idiopathic pulmonary fibrosis or IPF.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A new IPF treatment would address an unmet medical need. IPF is a chronic, progressive form of lung disease characterized by scarring of lung tissue and has limited treatment options. The joint Bristol-Myers and Duke team will work to develop and conduct a phase 2 study that is expected to begin later this year.
Princeton, New Jersey-based Bristol-Myers has collaborated with the Durham, North Carolina institute previously in cardiology, endocrinology and oncology. The partnership could also see Bristol-Myers and Duke working together on ways to accelerate the progress of drug candidates into proof-of-concept studies, improving clinical trial enrollment and developing disease educational programs.
“More and more, scientific innovation in drug development is happening at the crossroad of different disciplines; so, it is important to nurture relationships at these crossroads,” Dr. Elliot Sigal, Bristol-Myers executive vice president, chief scientific officer and president of R&D, said in a statement.
[Lung image from The Cleveland Clinic]
